INTERLEUKIN GENETICS INC
INTERLEUKIN GENETICS INC (ILIU): 4 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.0 months
D/E -1.38 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for INTERLEUKIN GENETICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$791K
Quarterly Burn
$1.5M
Runway
2.0 mo
Revenue
$141K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| anti-sense | Phase 2 |
| canikinumab | Phase 3 |
| periopredict | Approved |
| testing services for clinical trials | Preclinical |
Frequently asked questions
How many drug candidates are in INTERLEUKIN GENETICS INC's pipeline?
INTERLEUKIN GENETICS INC (ILIU) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INTERLEUKIN GENETICS INC's lead drug candidate?
INTERLEUKIN GENETICS INC's most advanced tracked candidate is anti-sense (Phase 2) for reduce Lp(a) levels.
What is INTERLEUKIN GENETICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INTERLEUKIN GENETICS INC has approximately 2.0 months of cash runway.
Get the full picture on INTERLEUKIN GENETICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.